Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma

BACKGROUND: There is no standard therapeutic procedure for the hepatocellular carcinoma (HCC) in patients with poor hepatic reserve function. With the approval of newly developed chemotherapeutic agent of miriplatin, we have firstly conducted the phase I study of CDDP powder (DDP-H) and miriplatin c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamimura, Kenya, Suda, Takeshi, Tamura, Yasushi, Takamura, Masaaki, Yokoo, Takeshi, Igarashi, Masato, Kawai, Hirokazu, Yamagiwa, Satoshi, Nomoto, Minoru, Aoyagi, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482551/
https://www.ncbi.nlm.nih.gov/pubmed/22994941
http://dx.doi.org/10.1186/1471-230X-12-127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3482551/
https://www.ncbi.nlm.nih.gov/pubmed/22994941
http://dx.doi.org/10.1186/1471-230X-12-127

Ejemplares similares